Jiangsu Bioperfectus Technologies Co Ltd
688399
Company Profile
Business description
Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products portfolio includes Fever respiratory pathogen detection series, Fever with a rash pathogen test series, Fever with bleeding pathogen test series, Foodborne diseases and diarrheal pathogen detection and Other types of pathogen detection series.
Contact
3rd floor, Block G19, No.1 Yaocheng Avenue
Jiangsu
Taizhou
CHNT: +86 52386201616
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
592
Stocks News & Analysis
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
stocks
Cisco earnings: AI orders and profitability look strong despite second-half choppiness
We’ve raised our fair value estimate of Cisco stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.20 | 16.20 | -0.18% |
| CAC 40 | 8,340.56 | 27.32 | 0.33% |
| DAX 40 | 24,852.69 | 3.46 | -0.01% |
| Dow JONES (US) | 49,694.37 | 427.03 | -0.85% |
| FTSE 100 | 10,402.44 | 69.67 | -0.67% |
| HKSE | 27,032.54 | 233.84 | -0.86% |
| NASDAQ | 22,726.81 | 339.66 | -1.47% |
| Nikkei 225 | 57,639.84 | 10.70 | -0.02% |
| NZX 50 Index | 13,427.44 | 79.84 | -0.59% |
| S&P 500 | 6,872.16 | 69.31 | -1.00% |
| S&P/ASX 200 | 8,965.50 | 7.40 | -0.08% |
| SSE Composite Index | 4,134.02 | 2.03 | 0.05% |